Tempest Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2024
Filed with the SEC on Mar 27, 2025 and accepted by EDGAR at Mar 27, 2025, 16:35 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2024-01-01 to 2024-12-31 | −$42.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2024-01-01 to 2024-12-31 | $1.3m | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months2024-01-01 to 2024-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2024-01-01 to 2024-12-31 | −$41.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | −$1.50 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | −$1.50 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2024-01-01 to 2024-12-31 | 27,901,739 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −$33.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | $435.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-12-31 | $30.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $31.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $41.5m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $14.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $22.4m | us-gaap:Liabilities |
| Long-term debt | At period end2024-12-31 | $0 | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-12-31 | $6.4m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-12-31 | $19.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-25-046144. Last ingested by Listed: Oct 26, 2026, 16:06 ET. Listed shows no prices and gives no investment advice.